1380487-15-9

Usage

Type

Synthetic organic compound

Usage

Commonly used in the pharmaceutical industry as a potential drug candidate

Derivative

Chlorinated derivative of 3,4-pyridinediamine

Functional Group

Cyclopropyl group attached to the nitrogen atom

Biological Activity

Studied as a kinase inhibitor for potential cancer treatments

Additional Potential

Exhibits promise as an antifungal agent

Importance

Significant target for further research and development in medicinal chemistry.

Upstream product

• 607373-83-1 2-chloro-4-methoxy-5-nitro-pyridine 

Downstream Products

• 1449665-26-2 1-cyclopropyl-N-(2-ethylphenyl)-N-methyl-1H-imidazo[4,5-c]pyridin-6-amine 
• 1449669-35-5 (1-cyclopropyl-1H-imidazo[4,5-c]pyridin-6-yl)-(2-ethylphenyl)amine 

Relevant academic research and scientific papers

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, wherein R1 and Cy are as disclosed herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

IMIDAZO [4, 5 -C] PYRIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Wherein R1, L1, R3, R4, Cy, L2 and R5 are as defined herein. Novel imidazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.